PRK with MMC as good as LASIK

Article

Wavefront-guided photorefractive keratectomy (PRK) with mitomycin C (MMC) offers very similar results, when correcting compound myopic astigmatism, to wavefront-guided LASIK surgery.

Wavefront-guided photorefractive keratectomy (PRK) with mitomycin C (MMC) offers very similar results, when correcting compound myopic astigmatism, to wavefront-guided LASIK surgery, according to Mauro Campos and colleagues from the Federal University of Sao Paulo, Brazil.

In a prospective, masked, randomized, contralateral eye controlled clinical trial, 84 eyes of 42 patients received customized PRK with MMC in one eye and customized LASIK in the fellow eye. The same postoperative regimens were used in both eyes.

Mean preoperative spherical equivalent (SE) correction was -3.79±1.10 D (PRK) and -3.94±1.18 D (LASIK). At one-year follow-up the percentage of eyes in the PRK group with 0.0, -0.1, -0.2 and -0.3 log MAR uncorrected visual acuity (UCVA) was 13%, 37%, 46% and 4%, respectively and 21%, 54%, 25% and 0%, respectively in the LASIK group. Mean cycloplegic refractive error was +0.48±0.37 D in the PRK group and +0.45±0.54 D in the LASIK group.

The researchers concluded that PRK with MMC is an effective method for correcting compound myopic astigmatism and produces very similar results to wavefront-guided LASIK.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.